What are Xanthine oxidase inhibitor drugs?

Xanthine oxidase inhibitor drugs are pharmacologic agents that share a common mechanism (typically targeting Xanthine oxidase). 6 are currently marketed, with 5 more in clinical development.

What are the marketed Xanthine oxidase inhibitor drugs?

Marketed Xanthine oxidase inhibitor drugs include allopurinol sustained-release capsules, AL, Febuxostat Tablets, Aloprim, Allopurinol Tablet, Uloric.

Xanthine oxidase inhibitor

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

6 marketed 3 in Phase 3 2 in Phase 2

This page covers all Xanthine oxidase inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Xanthine oxidase, xanthine oxidase, Xanthine dehydrogenase/oxidase.

Targets

Xanthine oxidase · xanthine oxidase · Xanthine dehydrogenase/oxidase · AMPK (AMP-activated protein kinase) / Xanthine oxidase pathway · Purine synthesis pathway (azathioprine); xanthine oxidase (allopurinol) · PDGF receptor, Xanthine oxidase

Marketed (6)

allopurinol sustained-release capsules · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Rheumatology / Metabolic disorders
Allopurinol inhibits xanthine oxidase, the enzyme responsible for converting hypoxanthine and xanthine to uric acid, thereby reducing serum and urinary uric acid levels.
AL · Medecins Sans Frontieres, Netherlands · Rheumatology
Allopurinol works by inhibiting the enzyme xanthine oxidase, which is involved in the production of uric acid.
Febuxostat Tablets · Mostafa Bahaa
Aloprim · Casper Pharma Llc · Oncology
Aloprim works by inhibiting the enzyme xanthine oxidase, which is responsible for producing uric acid in the body.
Allopurinol Tablet · Haiphong University of Medicine and Pharmacy · Rheumatology / Metabolic disorders
Allopurinol inhibits xanthine oxidase, an enzyme that converts hypoxanthine and xanthine to uric acid, thereby reducing serum and urinary uric acid levels.
Uloric · Takeda · Immunology
Uloric works by blocking the enzyme xanthine dehydrogenase/oxidase, which is involved in the production of uric acid.

Phase 3 pipeline (3)

Febuxostat IR · Takeda · Rheumatology
Febuxostat is a selective xanthine oxidase inhibitor that reduces uric acid production by blocking the enzyme responsible for converting hypoxanthine and xanthine to uric acid.
Bempedoic Acid Tablet · Gan & Lee Pharmaceuticals. · Rheumatology / Metabolic Disease
Bempedoic acid inhibits AMPK-activated protein kinase to reduce uric acid production and lower serum uric acid levels.
Azathioprine and Allopurinol · Hvidovre University Hospital · Immunology
Azathioprine suppresses the immune system by inhibiting purine synthesis, while allopurinol reduces uric acid production by inhibiting xanthine oxidase.

Phase 2 pipeline (2)

Combination - Tranilast and Febuxostat · Nuon Therapeutics, Inc. · Oncology, Cardiovascular
Tranilast is a selective inhibitor of PDGF receptors, while Febuxostat is a xanthine oxidase inhibitor.
Combination - Tranilast and Allopurinol · Nuon Therapeutics, Inc. · Rheumatology, Allergy
Tranilast inhibits the activity of mast cells and platelets, while Allopurinol inhibits xanthine oxidase.

Patent intelligence

xanthine oxidase inhibitor patent landscape — aggregated cliff calendar, attackable patents, originator estates